title: Sustained hypophosphatemic effect of once-daily niacin/laropiprant in dyslipidemic CKD stage 3 patients.
authors.forename: Joachim H
authors.initials: JH
authors.lastname: Ix
authors.forename: Prerna
authors.initials: P
authors.lastname: Ganjoo
authors.forename: Diane
authors.initials: D
authors.lastname: Tipping
authors.forename: Andrew M
authors.initials: AM
authors.lastname: Tershakovec
authors.forename: Andrew G
authors.initials: AG
authors.lastname: Bostom
mesh_terms: D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D050171:Dyslipidemias / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000009:adverse effects; D017674:Hypophosphatemia / Q000097:blood / Q000139:chemically induced*; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects*; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications*; D008055:Lipids / Q000097:blood*; D009525:Niacin / Q000008:administration & dosage / Q000009:adverse effects*; D016896:Treatment Outcome
chemical_list: D000960:Hypolipidemic Agents; D007211:Indoles; D008055:Lipids; C518174:MK-0524; D009525:Niacin